Dr. Weber on Combination Strategies for BRAF-Mutant Melanoma

Video

In Partnership With:

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.

There is an "urban legend" that patients who receive BRAF/MEK inhibition in the frontline setting will relapse. However, this is simply not true, Weber says. There is a plateau on the survival curve as researchers now have longer follow-up on survival from related studies. In the frontline and even in the second-line setting, there is a 35% plateau of survival at 3 to 4 years, implying that some patients, especially those with low-disease burden, may do very well with this regimen.

What is novel in the field is that the biomarker for the success of combined BRAF/MEK inhibition is low disease burden, low lactate dehydrogenase, and no brain metastases. This likely reflects a patient population that is immunologically responsive. It would suggest that these patients may have excellent outcomes with BRAF/MEK combinations, Weber adds.

Related Videos
Raj Singh, MD
Saad J. Kenderian, MB, CHB
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD